Purpose

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of therapeutic outcomes for patients with chronic hepatitis B (HBV) who are currently taking tenofovir alafenamide (TAF) relative to those patients following other treatment regimens. The study will address important clinical questions regarding the management of HBV with TAF and other oral therapies by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to TAF.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Criteria


Inclusion Criteria:

- Male or female patients, age ≥18 years

- On a stable antiviral therapy regimen for hepatitis B as determined by treating
physician

Exclusion

- Inability to provide written informed consent/assent

- Known coinfection with hepatitis Delta

- Known history of Human Immunodeficiency Virus (HIV)

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
tenofovir alafenamide Patients with a medication history of tenofovir alafenamide (TAF).
  • Other: TAF
    Patients who have a medication history of TAF

More Details

NCT ID
NCT03692897
Status
Active, not recruiting
Sponsor
Target PharmaSolutions, Inc.

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.